These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 30945328)

  • 21. Managing Patients With TP53-Deficient Chronic Lymphocytic Leukemia.
    Edelmann J; Gribben JG
    J Oncol Pract; 2017 Jun; 13(6):371-377. PubMed ID: 28605616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib.
    Maffei R; Fiorcari S; Martinelli S; Potenza L; Luppi M; Marasca R
    J Hematol Oncol; 2015 May; 8():60. PubMed ID: 26022368
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Idelalisib, ibrutinib show benefits in CLL.
    Cancer Discov; 2014 Apr; 4(4):382. PubMed ID: 24706642
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
    Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V
    Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO).
    Godet S; Protin C; Dupuis J; Dartigeas C; Bastie JN; Herbaux C; Leblond V; de Guibert S; Ghez D; Brion A; Ysebaert L; Delmer A; Quinquenel A
    Am J Hematol; 2018 Feb; 93(2):E52-E54. PubMed ID: 29164674
    [No Abstract]   [Full Text] [Related]  

  • 26. Idelalisib Bolsters CLL Regimen.
    Leslie M
    Cancer Discov; 2016 Mar; 6(3):OF2. PubMed ID: 26772993
    [No Abstract]   [Full Text] [Related]  

  • 27. Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials.
    Jones J; Mato A; Coutre S; Byrd JC; Furman RR; Hillmen P; Osterborg A; Tam C; Stilgenbauer S; Wierda WG; Heerema NA; Eckert K; Clow F; Zhou C; Chu AD; James DF; O'Brien SM
    Br J Haematol; 2018 Aug; 182(4):504-512. PubMed ID: 29873072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience.
    Autore F; Innocenti I; Morelli F; Sorà F; Corbingi A; Fianchi L; Criscuolo M; Pagano L; Sica S; Laurenti L
    Hematol Oncol; 2019 Oct; 37(4):496-497. PubMed ID: 31017684
    [No Abstract]   [Full Text] [Related]  

  • 29. Appendix 4: Chronic lymphocytic leukaemia: eUpdate published online 27 June 2017 (www.esmo.org/Guidelines/Haematological-Malignancies).
    ESMO Guidelines Committee
    Ann Oncol; 2017 Jul; 28(suppl_4):iv149-iv152. PubMed ID: 28881925
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia.
    Lampson BL; Kim HT; Davids MS; Abramson JS; Freedman AS; Jacobson CA; Armand PA; Joyce RM; Arnason JE; Rassenti LZ; Kipps TJ; Fein J; Fernandes SM; Hanna JR; Fisher DC; Brown JR
    Blood Adv; 2019 Apr; 3(7):1167-1174. PubMed ID: 30967392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies.
    Mato AR; Samp JC; Gauthier G; Terasawa E; Brander DM
    Cancer Biol Ther; 2018 Jul; 19(7):636-643. PubMed ID: 29584544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels.
    Shanafelt TD; Borah BJ; Finnes HD; Chaffee KG; Ding W; Leis JF; Chanan-Khan AA; Parikh SA; Slager SL; Kay NE; Call TG
    J Oncol Pract; 2015 May; 11(3):252-8. PubMed ID: 25804983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib.
    Vitale C; Ahn IE; Sivina M; Ferrajoli A; Wierda WG; Estrov Z; Konoplev SN; Jain N; O'Brien S; Farooqui M; Keating MJ; Wiestner A; Burger JA
    Haematologica; 2016 Jun; 101(6):e254-8. PubMed ID: 27013651
    [No Abstract]   [Full Text] [Related]  

  • 34. Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
    Michallet AS; Dilhuydy MS; Subtil F; Rouille V; Mahe B; Laribi K; Villemagne B; Salles G; Tournilhac O; Delmer A; Portois C; Pegourie B; Leblond V; Tomowiak C; de Guibert S; Orsini F; Banos A; Carassou P; Cartron G; Fornecker LM; Ysebaert L; Dartigeas C; Truchan Graczyk M; Vilque JP; Aurran T; Cymbalista F; Lepretre S; Lévy V; Nguyen-Khac F; Le Garff-Tavernier M; Aanei C; Ticchioni M; Letestu R; Feugier P
    Lancet Haematol; 2019 Sep; 6(9):e470-e479. PubMed ID: 31324600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare.
    Hampel PJ; Call TG; Ding W; Muchtar E; Kenderian SS; Wang Y; Leis JF; Witzig TE; Koehler AB; Fonder AL; Schwager SM; Rabe KG; Van Dyke DL; Braggio E; Slager SL; Kay NE; Parikh SA
    Am J Hematol; 2020 Mar; 95(3):E57-E60. PubMed ID: 31788844
    [No Abstract]   [Full Text] [Related]  

  • 36. Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
    Coutré SE; Furman RR; Flinn IW; Burger JA; Blum K; Sharman J; Jones J; Wierda W; Zhao W; Heerema NA; Johnson AJ; Tran A; Zhou C; Bilotti E; James DF; Byrd JC; O'Brien S
    Clin Cancer Res; 2017 Mar; 23(5):1149-1155. PubMed ID: 28073846
    [No Abstract]   [Full Text] [Related]  

  • 37. Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.
    Sanford DS; Wierda WG; Burger JA; Keating MJ; O'Brien SM
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):385-91. PubMed ID: 25817936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.
    Montraveta A; Lee-Vergés E; Roldán J; Jiménez L; Cabezas S; Clot G; Pinyol M; Xargay-Torrent S; Rosich L; Arimany-Nardí C; Aymerich M; Villamor N; López-Guillermo A; Pérez-Galán P; Roué G; Pastor-Anglada M; Campo E; López-Guerra M; Colomer D
    Oncotarget; 2016 Feb; 7(5):5507-20. PubMed ID: 26701728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
    Soumerai JD; Ni A; Darif M; Londhe A; Xing G; Mun Y; Kay NE; Shanafelt TD; Rabe KG; Byrd JC; Chanan-Khan AA; Furman RR; Hillmen P; Jones J; Seymour JF; Sharman JP; Ferrante L; Mobasher M; Stark T; Reddy V; Dreiling LK; Bhargava P; Howes A; James DF; Zelenetz AD
    Lancet Haematol; 2019 Jul; 6(7):e366-e374. PubMed ID: 31109827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL.
    Ahn IE; Basumallik N; Tian X; Soto S; Wiestner A
    Blood; 2019 May; 133(22):2452-2455. PubMed ID: 30917955
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.